From: Survival benefits of adding simvastatin to standard therapy for secondary prevention of bleeding esophageal varices in patients with hepatitis C-related liver cirrhosis
Child score
Group I
Group II
Total
A
N
8
9
17
%
20.0%
22.5%
21.3%
B
21
19
40
52.5%
47.5%
50.0%
C
11
12
23
27.5%
30.0%
28.8%
80
100.0%
Chi-square
X2
0.202
p-value
0.904